Medicare Will Cover New Class of Alzheimer Drugs if Fully Approved by FDA, With Limits
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
FRIDAY, June 2, 2023 -- Medicare will soon cover a new class of drugs for Alzheimer disease if they receive full approval from the U.S. Food and Drug Administration, with some key limits.
Along with full approval, drug makers will also have to gather and keep data in a registry showing how the drugs are working in the real world, the U.S. Centers for Medicare & Medicaid Services announced Thursday.
"Alzheimer's disease takes a toll on not just the people suffering from the disease but also on their loved ones and caregivers in a way that almost no other illness does. CMS has always been committed to helping people obtain timely access to innovative treatments that meaningfully improve care and outcomes for this disease," CMS Administrator Chiquita Brooks-LaSure said in a statement announcing the change. "If the FDA grants traditional approval, CMS is prepared to ensure anyone with Medicare Part B who meets the criteria is covered."
The drugs in question -- lecanemab (Leqembi) and aducanumab (Aduhelm) -- have already been given accelerated approval to "fill an unmet medical need" while drug makers continue research on their effectiveness and safety. But neither drug has received full, traditional approval.
Not everyone was thrilled with the idea of collecting real-world data in a registry. In a statement, the Alzheimer's Association called the registry requirement "an unnecessary barrier," adding that the registry "should not be a requirement for coverage" of an FDA-approved treatment.
However, the CMS said there is a "strong precedent" for using registries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Socioeconomic Status Transitions Tied to Dementia Risk
THURSDAY, May 23, 2024 -- Upward and downward socioeconomic status (SES) transitions are associated with the risk for dementia and the length of dementia-free periods during the...
Ultraprocessed Food Consumption Linked to Cognitive Impairment, Stroke
THURSDAY, May 23, 2024 -- The levels of food processing is associated with cognitive impairment and stroke, according to a study published online May 22 in Neurology. Varun M...
Study Identifies Factors That Predict Driving Cessation in Seniors
WEDNESDAY, May 22, 2024 -- Among older adults, factors associated with future driving cessation include female sex and neuropsychological measures of cognitive functioning...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.